Zydus Cadila gets USFDA nod to market anti-viral drug

AHMEDABAD | MUMBAI | RAJKOT – Dr Pankaj Patel led Zydus Cadila Group got US FDA (Food and Drugs Administration) nod to market anti-viral drug Acyclovir Sodium Injection in composition of 500 mg and 1,000 mg, Cadila Healthcare Ltd said today, in a press release submitted to the Exchanges in India.

Zydus Cadila has received the final approval from the USFDA to market Acyclovir Sodium Injection, 500 mg (base)/10 mL (50 mg (base)/mL) and 1,000 mg (base)/20mL (50 mg (base)/mL) single-dose vials (USRLD —Zovirax® for injection), the release read.

It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

Acyclovir is an antiviral drug. It slows the growth and spread of the herpes virus in the body.

Acyclovir injection is usedto treat severeinfectionscausedby herpesviruses,including severe formsof genital herpes, shingles (varicella-zoster), herpes encephalitis (swelling of the brain), neonatal herpes infection and herpes infections in people with other diseases that weaken the immune system.

The group now has 216 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Immediately after the company’s announcement of having received USFDA approval to market anti-viral drug in injection form hit the Indian Stock Markets, instant spike of price improvement was observed in the share price of Cadila Healthcare and the shares continued trading in GREEN Zone, ending on positive counters, today.